A Shanghai court has imposed spending limits on Chinese mRNA vaccine maker Stemirna Therapeutics Co. Ltd. for failing to make good on its debts, exacerbating the woes of the one-time investor darling as it struggles to raise fresh financing in the face of falling demand for Covid treatments.
China mRNA Vaccine-Maker Stemirna Struggles With Debt Crisis
2023年10月20日 20:15
One-time investor darling seeks fresh capital as CEO admits it is in a ‘difficult’ position as it awaits final Covid vaccine approvals in China
![]()
- Photo: VCG
[财新双语通产品，是为有双语需求读者专门订制的优惠产品， 按此可享超值优惠订阅。]
版面编辑：喻竹杨洋
图片推荐
视听推荐
编辑推荐
最新文章
- 15:05河南三门峡入黄河口处修堤坝影响行洪安全
- 12:00徐林：加入高标准自由贸易协定，需应对好...
- 11:36潘功胜：为“三大工程”建设提供中长期低...
- 11:32发达与不发达国家对接支持非洲能源转型承...
- 22:31国家卫健委：未发现新发传染病，接种流感...
- 22:12香港今年前十月累计27名学生自杀 港府...
- 18:28BDI重上3000点创18个月新高 海...
- 18:19中盐旗下“两碱”公司废液晾晒场威胁柴达...
- 14:56COP28首份草案呼吁减少或淘汰化石燃...
- 12:42美国发布《通胀削减法案》外国敏感实体指南
京公网安备 11010502034662号 